CG Oncology, Inc. (CGON)
67.15
-1.61
(-2.34%)
USD |
NASDAQ |
Sep 25, 16:00
67.17
+0.02
(+0.03%)
After-Hours: 19:59
CG Oncology Total Liabilities (Quarterly) : 56.54M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 56.54M |
| March 31, 2026 | 43.48M |
| December 31, 2025 | 38.99M |
| September 30, 2025 | 42.27M |
| June 30, 2025 | 31.09M |
| March 31, 2025 | 23.42M |
| December 31, 2024 | 21.42M |
| September 30, 2024 | 15.70M |
| Date | Value |
|---|---|
| June 30, 2024 | 11.97M |
| March 31, 2024 | 10.17M |
| December 31, 2023 | 14.51M |
| September 30, 2023 | 12.02M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 22.57M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.086B |
| Shareholders Equity (Quarterly) | 1.029B |
| Debt to Equity Ratio | 0.0086 |
| Current Ratio | 22.22 |
| Net Debt Paydown Yield | -0.02% |